» Articles » PMID: 18028479

Bone Marrow Microvessel Density in Chronic Myeloproliferative Disorders: a Study of 115 Patients with Clinicopathological and Molecular Correlations

Overview
Journal Br J Haematol
Specialty Hematology
Date 2007 Nov 22
PMID 18028479
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Philadelphia-negative chronic myeloproliferative disorders (CMD) include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). Angiogenesis is critical in the pathogenesis of PMF. We studied angiogenesis in 115 patients with CMD (23 PV, 24 ET, 46 PMF, 12 post-PV and 10 post-ET myelofibrosis) by assessment of microvessel density (MVD) in bone marrow (BM). Kruskall-Wallis analysis of variance showed that patients with PMF had significantly higher values of MVD than those with PV (P < 0.001), ET (P < 0.001) and controls (P < 0.001). Mann-Whitney U-test demonstrated that patients with PMF at the prefibrotic stage had significantly higher MVD values than those with ET (P = 0.02). Patients with post-PV myelofibrosis showed significantly higher MVD values than those with PV (P < 0.001), as did patients with post-ET myelofibrosis compared with ET (P < 0.001). In patients with CMD, the multivariate generalized linear regression model showed that the JAK2 (V617F) mutational burden (P = 0.01), serum lactate dehydrogenase level (P = 0.003), and anaemia (P < 0.001) independently correlated with MVD. In summary, this study indicates that assessment of BM angiogenesis, as measured by MVD, may be a useful additional tool in the histopathological definition of CMD.

Citing Articles

ADAMTS13, von Willebrand Factor, Platelet Microparticles, Factor VIII, and Impact of Somatic Mutations in the Pathogenesis of Splanchnic Vein Thrombosis Associated with BCR-ABL-Negative Myeloproliferative Neoplasms.

Castelli R, Berzuini A, Manetti R, Delitala A, Castro D, Sanna G Life (Basel). 2024; 14(4).

PMID: 38672756 PMC: 11051276. DOI: 10.3390/life14040486.


Study of significance of bone marrow microvessel density in myeloproliferative neoplasms in correlation with CD34 blasts, mast cell count and fibrosis.

Thomas K, Rao R, G V C, Rai S, Rao A R S, Vatsala K F1000Res. 2024; 12:503.

PMID: 38434629 PMC: 10905004. DOI: 10.12688/f1000research.130522.2.


CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis.

Vermeersch G, Proost P, Struyf S, Gouwy M, Devos T Haematologica. 2024; 109(7):2060-2072.

PMID: 38426279 PMC: 11215396. DOI: 10.3324/haematol.2023.284921.


Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.

Hasselbalch H, Junker P, Skov V, Kjaer L, Knudsen T, Larsen M Cancers (Basel). 2023; 15(17).

PMID: 37686599 PMC: 10486581. DOI: 10.3390/cancers15174323.


Systematic dissection of coordinated stromal remodeling identifies Sox10 glial cells as a therapeutic target in myelofibrosis.

Sarkaria S, Zhou J, Bao S, Zhao W, Fang Y, Que J Cell Stem Cell. 2023; 30(6):832-850.e6.

PMID: 37267917 PMC: 10240254. DOI: 10.1016/j.stem.2023.05.002.